A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation.
1995
In a double-blind, randomized, placebo-controlled trial, BT563, a murine IgGt anti-IL-2R antibody, was given as a rejection prophylaxis after kidney transplantation. Drug-related side effects were not observed. During the 10-day course of BT563, no rejections (0/27) were found, whereas a rejection e
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
62
Citations
NaN
KQI